Immunic, inc. reports first quarter 2024 financial results and provides corporate update

– substantially bolstered balance sheet through a three-tranche private placement totaling up to $240 million, extending cash runway into the third quarter of 2025, based on initial $80 million tranche – – received fourth u.s. patent directed to use of vidofludimus calcium in multiple sclerosis; multilayered intellectual property strategy provides protection into 2041 in the united states – – twin phase 3 ensure trials in relapsing multiple sclerosis and phase 2 calliper trial in progressive multiple sclerosis remain underway – – webcast to be held today, may 8, 2024, at 8:00 am et – new york , may 8, 2024 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended march 31, 2024, and provided a corporate update. "during the first quarter and subsequent period, we have continued to advance both the phase 2 calliper trial in patients with progressive multiple sclerosis (pms) and the twin phase 3 ensure trials in relapsing multiple sclerosis (rms), for our potentially groundbreaking, orally available lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838)," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking